No Data
No Data
KalVista Shares New Data on HAE Pill, Highlighting Early Treatment Results at ACAAI Conference
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Presents New Data Showing Effectiveness Of Sebetralstat In Reducing Anxiety During Attacks; Supports Need For Oral On-Demand Option To Treat Attacks Earlier And More Often At The 2024 HAEi Global Angioedema Forum
No Data
No Data